Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) was downgraded by research analysts at J P Morgan Chase & Co from a “neutral” rating to an “underweight” rating in a research report issued to clients and investors on Thursday, Marketbeat.com reports. They presently have a $12.00 target price on the specialty pharmaceutical company’s stock. J P Morgan Chase & Co’s price objective suggests a potential downside of 43.40% from the company’s current price.

Several other equities research analysts have also commented on VRX. Wells Fargo & Company reiterated an “underperform” rating and issued a $8.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Saturday, September 30th. Cantor Fitzgerald restated a “buy” rating and set a $23.00 price target on shares of Valeant Pharmaceuticals International in a research note on Thursday, September 28th. Vetr upgraded shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “sell” rating and set a $12.46 price target for the company in a research note on Thursday, September 28th. Piper Jaffray Companies restated a “sell” rating and set a $14.00 price target on shares of Valeant Pharmaceuticals International in a research note on Sunday, September 17th. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $17.00 price objective on shares of Valeant Pharmaceuticals International in a report on Monday, September 18th. Six analysts have rated the stock with a sell rating, ten have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $17.72.

Valeant Pharmaceuticals International (VRX) traded up $1.49 during trading hours on Thursday, reaching $21.20. 27,019,422 shares of the company’s stock traded hands, compared to its average volume of 18,377,553. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26. The stock has a market cap of $6,870.75, a price-to-earnings ratio of 3.20, a price-to-earnings-growth ratio of 0.54 and a beta of -0.22. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $22.81.

In other news, Director John Paulson purchased 344,216 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was purchased at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the acquisition, the director now directly owns 94,559 shares in the company, valued at $1,361,649.60. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 5.87% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the business. Riggs Asset Managment Co. Inc. boosted its holdings in Valeant Pharmaceuticals International by 118.2% in the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock valued at $119,000 after purchasing an additional 4,512 shares during the period. Cetera Investment Advisers bought a new position in Valeant Pharmaceuticals International in the 2nd quarter valued at $192,000. Harbour Capital Advisors LLC bought a new position in Valeant Pharmaceuticals International in the 3rd quarter valued at $224,000. American Century Companies Inc. bought a new position in Valeant Pharmaceuticals International in the 3rd quarter valued at $238,000. Finally, Moors & Cabot Inc. boosted its holdings in Valeant Pharmaceuticals International by 32.3% in the 2nd quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock valued at $267,000 after purchasing an additional 3,725 shares during the period. 49.49% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Valeant Pharmaceuticals International (VRX) Lowered to Underweight at J P Morgan Chase & Co” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/valeant-pharmaceuticals-international-vrx-cut-to-underweight-at-j-p-morgan-chase-co/1763038.html.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.